Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotech Startup Investors in October 2024

Last updated: Oct 2024 A list of 50 angel investors and VC (Venture Capital) funds that invest in Biotech startups. We rank investors based on the number of investments they made in Biotech companies. This investor list updates every month.

Top 50 Biotech Startup Investors in October 2024

Investor	Biotech investments
SOSV	261
ARCH Venture Partners	126
OrbiMed	102
Sofinnova Partners	93
Alexandria Venture Investments	88
Novo Holdings	82
Versant Ventures	80
New Enterprise Associates	79
F-Prime Capital	78
Atlas Venture	71
Khosla Ventures	69
RA Capital Management	68
5AM Ventures	66
Polaris Partners	66
Qiming Venture Partners	65
MPM Capital	64
Innova Memphis	63
Third Rock Ventures	59
M Ventures	59
Novartis Venture Fund	59
UK Innovation & Science Seed Fund	56
Bpifrance	54
Sequoia Capital China	53
Canaan Partners	52
HTGF \| High-Tech Gruenderfonds	52
Boehringer Ingelheim Venture Fund	50
BioAdvance	50
Pfizer Venture Investments	49
Lux Capital	49
Google Ventures	48
Fifty Years	47
Andreessen Horowitz	47
Takeda Ventures	47
DCVC	47
EQT Life Sciences	45
Parkwalk Advisors	45
Sofinnova Investments	45
Lilly Asia Ventures	45
SR One	44
Seventure Partners	43
KdT Ventures	42
Hatteras Venture Partners	41
Forbion Capital Partners	41
The Column Group	41
Casdin Capital	41
Connecticut Innovations	40
Frazier Healthcare Partners	39
Scottish Enterprise	39
Amgen Ventures	38
Dolby Family Ventures	38

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, China, United Kingdom

Portfolio highlights

Vilya — Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology.
Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
Rippl Care — Dementia care for seniors, ready when you are

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

Chemomab — Pioneering Innovative Treatments for Patients with Fibrosis-Related Diseases
MBX Biosciences — Homepage - MBX Biosciences
Brenig Therapeutics — Brenig Therapeutics develops therapies for neurodegenerative disorders.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

deepc — The Radiology AI Platform - Your effortless access to AI
Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, France, Canada

Portfolio highlights

Umaro Foods — Umaro Foods specializes in developing a plant-based protein source from ocean-farmed seaweed.
TwoStep Therapeutics — TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.
Bright Peak Therapeutics — Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases. At Bright Peak, they are creating innovative cytokine therapeutics that are uniquely engineered to precisely control and expand desired biological properties.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Draupnir Bio — Draupnir Bio is developing new innovative therapies for patients.
Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

SixPeaks Bio — SixPeaks is developing a pipeline of medicines for healthy weight loss.
Borealis Biosciences — Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.
Bright Peak Therapeutics — Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases. At Bright Peak, they are creating innovative cytokine therapeutics that are uniquely engineered to precisely control and expand desired biological properties.

Foundational partners to ambitious founders at every stage of company-building.

Investment focus

Software, Health Care, Biotechnology
Series B, Series A, Series C
United States, India, China

Portfolio highlights

Agree.com — Agree.com is the best solution for creating and managing contracts, streamlining negotiations, enhancing compliance, optimizing workflows, and converting more customers — all within one intuitive platform. View edits, track signatures, and get alerted on all upcoming key milestones. Include free, one-click e-signatures with identity verification onevery agreement. Increase deal velocity and drive revenue impact with integrated payments.
MBX Biosciences — Homepage - MBX Biosciences
Brenig Therapeutics — Brenig Therapeutics develops therapies for neurodegenerative disorders.

F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Series C
United States, United Kingdom, China

Portfolio highlights

Odaseva — Odaseva is the leading enterprise data platform for Salesforce. Industry leaders rely on Odaseva to keep data protected, compliant, and agile.
Chaos Labs — Chaos Labs is a fully automated on-chain economic security system that allows crypto protocols to optimize risk management and capital efficiency while safeguarding user funds. Chaos Labs offers a more secure and safe operating environment for crypto protocols. Chaos Labs uses technology and risk management expertise to help protocols navigate theoften volatile crypto markets and make informed decisions. The platform is currently available for protocols on the Ethereum network, with plans to expand to other blockchains such as Terra, NEAR, and Polygon in the future.
Rippl Care — Dementia care for seniors, ready when you are

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Disc Medicine — Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors.
GRO Biosciences — GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
Kailera Therapeutics — Kailera Therapeutics is a clinical-stage biotechnology company that provides revolutionary therapies for treating obesity and related diseases.

Khosla Ventures invests in companies that are bold, early and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Headquartered in Menlo Park, Calif., Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech,digital health, medtech and diagnostics, therapeutics and frontier technology.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Series B, Seed
United States, India, United Kingdom

Portfolio highlights

Noetik — Noetik is an AI-native biotechnology company. Our mission is to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
Father Son Matching Shirts — FatherSonMatchingShirts store offers a wide variety of apparel such as t-shirts, sweatshirts, hoodies, tank tops, and mugs. We're trying our best to bring customers. You are welcome to FatherSonMatchingShirts. We're trying our best to bring customers the shirts are made of high quality materials for maximum comfort in whatever you do.
Openwater — OPENWATER - THE FUTURE OF NEURAL DIAGNOSTICS IN THE PALM OF YOUR HAND.

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Series A
United States, United Kingdom, China

Portfolio highlights

Idrx — IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies.
MBX Biosciences — Homepage - MBX Biosciences
Navigator Medicines — Leading the advancement of biologics for targeted immune regulation & restoration.

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

RareCyte — Rarecyte provides precision medicine solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics.
TMRW Life Sciences — TMRW helps patients and clinics safely store their eggs and embryos
Tectonic Therapeutic — Tectonic and AVROBIO have completed their anticipated merger.Please follow this link to our press release for additional information.

Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series A, Series C
United States, Ireland, Singapore

Portfolio highlights

Noetik — Noetik is an AI-native biotechnology company. Our mission is to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Tectonic Therapeutic — Tectonic and AVROBIO have completed their anticipated merger.Please follow this link to our press release for additional information.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series A, Series C
China, United States, Hong Kong

Portfolio highlights

LTZ Therapeutics — LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
Zhongyi Rehabilitation — Zhongyi Rehabilitation is a provider of rehabilitation products and services that focuses on the operation of chain rehabilitation centers to provide patients with one-stop professional rehabilitation needs and solutions.
Chenzhang Biotechnology — Chenzhang Bio is a biotechnology developer specializing in stem cell storage and treatment technology. focusing on stem cell storage and treatment technologies, company's research and commercialization, enhancing its R&D team and promoting clinical application of stem cell treatment technology

Powering Breakthroughs in Life Sciences

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series A, Series C
United States, United Kingdom, Canada

Portfolio highlights

AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies

Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.

Investment focus

Health Care, Medical, Medical Device
Seed, Pre-Seed, Convertible Note
United States, Argentina, United Kingdom

Portfolio highlights

Rantizo — Fly more acres, deliver better service. The equipment, tools, and expertise you need to be the grower's first call for drone spray services.
iYOTAH Solutions — iYOTAH Solutions is a transformational SaaS technology company that connects data to help the animal protein industry thrive.
Glanris — Glanris developed a completely green, non-toxic, filtration media for water purification from an agriculture by-product. This agricultural product is grown around the world, is plentiful, and can be used locally to ensure clean drinking water in developing countries. It also gives local farmers a significant additional income source for a productthat today they are throwing away.This media has been independently tested over the last two years of development and is ready for production.

Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

Marea Therapeutics — Marea Therapeutics is a clinical-stage biotechnology firm that uses the most recent advancements in human genetics to create first-in-class, next-generation medications for cardiometabolic illnesses.
Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
Formo — We're Formo, the future of dairy. Using micro fermentation, we create animal-free cheeses that humans love.
NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
Exsilio Therapeutics — Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells.
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

HonuWorx — HonuWorx is a technology company providing autonomous systems aimed at lowering both expenses and the environmental impact of operating robotic systems. The company's software technology is an edge-cloud architected communications and control platform that enables geographically distributed stakeholders to see data, collaborate, supervise, andcontrol robotic systems that are beyond line-of-sight.
Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Wave Photonics — Wave Photonics utilizes computational techniques to accelerate integrated photonics product designs.The company is developing a platform that provides optimized designs and streamlined integration between the supply chain using a software tool for predicting the performance and variation of a component for a given fabrication process and anoptimizer to generate a foundry-specific component library.Wave Photonics is headquartered in Bristol, Bristol.

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
France, United States, Switzerland

Portfolio highlights

Tracklab — Tracklab is a B2B compliance software helping regulated companies manage their mandatory supplier documentations.
Jared — Jared is an early-stage fintech company that has developed the first intelligent financial assistant for the B2C Market that addresses the need for daily support in understanding and anticipating each individual’s financial needs and objectives.Managing finances is everyone's business, regardless of the amount of their incomes or wealth.Jared comes up to balance deep inequalities in our finances due to differences in financial education. Even if many support and advice solutions do exist (financial advisors, bank advisors, Agregators & Asset Management platform, roboadvisors etc.), they are ill-suited to a large part of the population. At a time when these tools are becoming ever more numerous, many people feel overwhelmed by the complexity of the financial world in which they live, and have difficulties making informed decisions: half of the population doesn’t have any financial goals defined (saving money, preparing its retirement, …). This underscores the need for a tool that helps people understand their own financial situation and recommends goals to achieve.The application is positioned as an interactive financial companion, transforming the crucial step of understanding one's financial situation. By merging advanced technologies with an intuitive user experience, Jared democratizes access to personalized financial information.Jared's innovative approach goes beyond raw data to analyze the financial psychology of each user. By integrating elements of behavioral finance and cognitive science, Jared deciphers the emotions and biases that influence financial decisions. The result is informed analysis and tailored recommendations that go beyond the numbers. Jared's content is tailored to the user's profile, assets and personality.1. Proactive financial education: Beyond simple notifications, Jared acts as an educational guide, providing contextual advice precisely when the user needs it. It transforms complex financial moments into learning opportunities, empowering users. 2. Simplicity and accessibility: By making complex financial information understandable and accessible, Jared democratizes financial management. Users benefit from a user-friendly interface that simplifies decision-making.3. Utilization of behavioral finance: We leverage insights from cognitive science not merely to acquaint ourselves with our users but to comprehensively understand them. We use unique psychometric tests specifically developed to identify hidden characteristics of user. This enables us to assess traits previously unexplored within the realm of finance, offering a deeper understanding of user behavior. 4. Unique competitive advantage in data: This competitive edge lies in our dynamic dataset. With an interactive nature, our dataset continually evolves, allowing us to refine the correlation between content and user profiles with each new data iteration. This agility empowers us to adapt our offerings in real-time, ensuring relevance and efficacy for our users.
Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.

We help founders build enduring companies.

Investment focus

Biotechnology, Health Care, Artificial Intelligence
Series A, Series B, Series C
China, United States, Australia

Portfolio highlights

Xingkeyuan — Star Science is a high-performance lithium battery silicon-carbon negative electrode material research and development company. It has achieved small-scale mass manufacture of nano-silicon as well as the experimental development of high-efficiency silicon-carbon composite materials.
UTA AI — Wanderboat is a travel + outing AI companion to find and sort the best point of interest with videos, images, and insights. From signature dishes to photo spots, you can ask questions freely in-chat, in-document, or on-map for personalized experiences.
Sanshou Technology — Sanshou Technology focuses on researching and developing smart motorcycles.

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.

Investment focus

Software, Biotechnology, Health Care
Series A, Series B, Series C
United States, United Kingdom, Israel

Portfolio highlights

Nagish — Nagish captions your phone calls and empowers you to talk using text or voice. It's fast, private, and free.
Aim Security — Aim is the industry guide to secure GenAI adoption, empowering security leaders to drive business productivity while ensuring proactive protection for all GenAI use cases.
Reibus — Reibus is the leading platform for buying and selling steel and other metals, with end-to-end services including logistics and financing.

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Information Technology, Biotechnology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

TRAIT — TRAIT Running Coach app for your iphone or ipad tablet.
DemoSquare — DemoSquare is a pioneer in the realm of public-affairs management connect businesses with government affairs by putting regulatory monitoring on autopilot.
ABH Optics ApS — ABH Optics provides the world's thinnest and lightest eyeglass lenses.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United States, Canada

Portfolio highlights

Senzo — SENZO HEALTH HAS DEVELOPED A REVOLUTIONARY LATERAL FLOW TEST WHICH DELIVERS THE SAME ACCURACY AS LABORATORY-BASED PCR, WITH RESULTS AVAILABLE WITHIN 10 MINUTES, AT A FRACTION OF THE COST.
KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
Palvella Therapeutics — Palvella Therapeutics is committed to developing safe and effective therapies that specifically target the root cause of genetic skin diseases.

Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Switzerland

Portfolio highlights

Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Investment focus

Software, Health Care, Biotechnology
Series A, Seed, Series B
United States, Canada, United Kingdom

Portfolio highlights

Magie — Magie is WhatsApp's first smart account, designed for people who understand the value of their time.Magie pays your invoices using WhatsApp and you may communicate with her via messages, audio, or photographs without ever having to enter into an app. Magic.
JOYA — JOYA is the first employee skincare and wellness benefit platform. The company's goal is to provide tailored access to services such as skin cancer screenings, skin condition treatment, anti-aging, acne, and hair loss care from reputable physicians at an accessible cost.
Impulse Space — Economical and nimble last-mile space payload delivery

GV supports innovative founders moving the world forward.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Seed
United States, United Kingdom, Canada

Portfolio highlights

Rippl Care — Dementia care for seniors, ready when you are
MOLO MOLO PAY — MOLO MOLO PAY est la première expérience d'achat basée sur l'épargne intégrée aux commerçants en Afrique francophone. Économisez maintenant, achetez plus tard.
Nym — Nym Health leverages advanced AI for medical coding, revolutionizing accuracy and speed within revenue cycle management. Discover the difference.

WE BACK HEROES using technology to solve the world's biggest problems

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Germany, Canada

Portfolio highlights

Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.
BillionToOne — We are a team at the forefront of disease detection focused on moving Prenatal Screening and Liquid Biopsy forward.
Waypoint Bio — Waypoint's proprietary spatial multi-omics platform enables us to solve critical issues around understanding how cell therapies navigate the three-dimensional tumor microenvironment and allow the measurement of cell-to-cell interactions.

Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.

Investment focus

Software, Information Technology, Internet
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

Viggle AI — Viggle AI is a pioneering Canadian firm that uses artificial intelligence to enable people of all skill levels to easily create high-quality animated video using simple text instructions.
Levels — Levels helps you see how food affects your health with data from biosensors like continuous glucose monitors (CGMs)
Safe Superintelligence — Safe Superintelligence is an artificial intelligence research lab that solves the technical challenge of building superhuman intelligence. The company operates a dedicated lab to advance capabilities while prioritizing safety through revolutionary engineering.

Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

OncoResponse — OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.
EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.

We are deep tech venture capital.

Investment focus

Software, Artificial Intelligence, Health Care
Seed, Series A, Series B
United States, Canada, United Kingdom

Portfolio highlights

Noetik — Noetik is an AI-native biotechnology company. Our mission is to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
Twelve — Twelve is a carbon transformation company converting captured carbon dioxide into valuable chemicals, fuels, and other essential products. Their technology eliminates emissions by turning CO2 into essential products that are made from fossil fuels. They specialize in the fields of CO2 electrocatalysis and electrochemical reactor design.
Zap Energy — Zap Energy's fusion reactor stabilizes plasma using sheared flows rather than magnetic fields. Driving electric current through the flow creates the magnetic field, which confines and compresses the plasma. The higher the current, the greater the pressure and density in the plasma. Zap Energy's reactor is the least expensive, mostcompact, most scalable solution with the shortest path to commercially viable fusion.

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
OW Smell Made Digital — OW Smell Made Digital offers software and hardware solutions for controlling smell.
Cambridge Electric Cement — Cambridge Electric Cement is a sustainable cement start-up. Its breakthrough process co-recycles steel and cement to produce a low carbon, circular cement product that offers very low emissions[1], circular, and scalable alternative to existing cement production.

Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series A, Series C
United States, France, Switzerland

Portfolio highlights

Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
Aeovian Pharmaceuticals — Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
China, United States, Hong Kong

Portfolio highlights

ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
Targeting One — Targeting One is an in-vitro diagnostic product developer.
Healingovation — Healingovation is a med-tech company that specializes in the development and manufacturing of surgical robots, intelligent diagnosis and treatment equipment.

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Renalys Pharma — Renalys Pharma is a private, late-stage clinical biopharmaceutical firm in Japan dedicated on developing new therapies that address unmet needs in the management of renal illness in Japanese and Asian patients.
Zenas BioPharma — Enabling patients with autoimmune diseases to reimagine life

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Investment focus

Biotechnology, Health Care, Software
Series A, Series B, Funding Round
France, United States, Germany

Portfolio highlights

ID5 — ID5 provides a comprehensive suite of identification services designed to improve to improve addressability and measurement across all environments
Peptobiotics — We make agriculture more productive, humane and sustainable by promoting growth and protecting against pathogens using a new new type of antibiotic alternative that does not cause resistance. Our recombinant peptides are synthetic biology products manufactured in a patent pending precision fermentation process. We are launching a range of products across livestock and aquaculture in Asia.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

KdT Ventures is the standard for early-stage frontier science investing.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Israel, Germany

Portfolio highlights

Marigold Health — Marigold Health is an anonymous social network where people with mental health and substance use conditions support each other.
Radar Therapeutics — Precision-targeted, smart therapies to conquer the world's most intractable diseases.
Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Funding Round
United States, Canada

Portfolio highlights

Endogenex — DyaMX is an early stage medical device company focused on the treatment of Type 2 Diabetes
AtaCor Medical — AtaCor Medical - Designing innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.
Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Navigator Medicines — Leading the advancement of biologics for targeted immune regulation & restoration.
Bicycle Therapeutics — Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

InduPro — InduPro is a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies.
Kenai Therapeutics — Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders. The company provides off-the-shelf neuron replacement medicines as effective disease-modifying treatments for neurological disorders, providing doctors with techniques to treat diseases like Parkinson's.
Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.

Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, France, China

Portfolio highlights

Idrx — IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies.
TMRW Life Sciences — TMRW helps patients and clinics safely store their eggs and embryos
BridgeBio Oncology Therapeutics — BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.

At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Funding Round
United States, Israel, Canada

Portfolio highlights

AmpUp — Commercial electric vehicle (EV) charging network solutions made simple for everyone. Easily manage and analyze EV charging data from a single dashboard.
Oxylus Energy — Oxylus Energy provides new carbon utilization technology for the generation of e-fuels It strives to make CO2 capture and conversion competitive, scalable, and circular for a decarbonized future.
Halda Therapeutics — Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states.

With its purpose-driven culture and deep industry expertise, Frazier Healthcare is the preferred partner to profitable healthcare companies.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Post-IPO Equity
United States, Canada, Ireland

Portfolio highlights

Metagenomi — Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
Pardes Biosciences — Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
New Amsterdam Pharma — NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

Chromacity — Chromacity manufacture the next generation of ultrafast lasers. Discover our fixed wavelength femtosecond lasers and picosecond OPOs.
Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!
Shot Scope — The official Shot Scope website. Golf watches, range finders and performance tracking that help lower your score and handicap. Buy direct online today!

Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Canada, United Kingdom

Portfolio highlights

Inversago Pharma — Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
Casma Therapeutics — Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
Feldan Therapeutics — Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle.

Dolby Family Ventures is an early stage venture firm focused on building great technology companies. They partner with best-in-class innovators and strong investment syndicate partners at the seed stage of a company’s development. Unlike many seed investors, They intend to continue to invest across future rounds in our successful portfoliocompanies.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Seed, Series B
United States, Austria, Israel

Portfolio highlights

Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
Esper Satellite Imagery — Welcome to Esper Satellite Imagery. Enjoy your Stay.

Investors by industry

Artificial intelligence